πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,257 results for β€œFirst” Clear

  1. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  2. HB0043

    The First People's Hospital of Lianyungang

    Acne Vulgaris

    phase 2 small molecule active

    1 trial

  3. HUMSCs combined with bovine type I collagen

    The First People's Hospital of Lianyungang

    Burn Wounds

    phase 2 other active

    1 trial

  4. Heparin and Rivaroxaban

    The First People's Hospital of Lianyungang

    Liver Cirrhosis

    phase 2 small molecule completed

    1 trial

  5. HiPSC-RPE cells

    The First People's Hospital of Lianyungang

    AMD - Age-Related Macular Degeneration

    phase 2 mab active

    1 trial

  6. Human Adipose-Derived Stem Cell Exosomes

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 2 mab active

    1 trial

  7. Humanized CD7 CAR-T cells

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 2 mab active

    1 trial

  8. IBI363

    The First People's Hospital of Lianyungang

    Advan'ce'd

    phase 2 small molecule active

    1 trial

  9. IL-15-armored CAR-T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Multiple Myeloma

    phase 2 mab active

    1 trial

  10. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  11. Icotinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Icotinib

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  13. Imatinib

    The First People's Hospital of Lianyungang

    Progression-free Survival

    phase 2 small molecule active

    1 trial

  14. Immunological Agent

    The First People's Hospital of Lianyungang

    Lung Cancer Metastatic

    phase 2 small molecule active

    1 trial

  15. Immunotherapy combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. Inetetamab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Inotuzumab OzogamicinΒ±Donor Lymphocyte Infusion

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Acute

    phase 2 small molecule active

    1 trial

  18. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    The First People's Hospital of Lianyungang

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  19. Intracavernosal administration of autologous ADRC

    The First People's Hospital of Lianyungang

    Erectile Dysfunction

    phase 2 other completed

    1 trial

  20. Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis of HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Intravenous esketamine using Dixon's up-and-down sequential method

    The First People's Hospital of Lianyungang

    Hepatic Neoplasm

    phase 2 small molecule active

    1 trial

  22. Iparomlimab and Tuvonralimab Injection (QL1706)

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  23. Iparomlimab and Tuvonralimab Injection in combination with TFOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  24. Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources